Compare Carparts.Com Inc (PRTS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Recursion Pharmaceuticals Inc — how do they compare? Carparts.Com Inc trades at $8.63 (market cap $66.42M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 32.2× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| PRTS | RXRX | |
|---|---|---|
Market Cap | $66.42M | $2.14B |
Volume | 40,287 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $6.79 |
52-Week Low | $3.88 | $2.84 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $79.39M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRTS trades at $8.51, down 2.13% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats but remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, though net losses improved in recent quarters. Analyst sentiment is positive with 60% buy ratings.
The outlook balances technical strength against fundamental challenges. While the stock shows bullish momentum and analyst support, persistent losses and declining revenue pose significant risks. Investment opportunity exists if the company can stabilize revenue and achieve profitability, but current financial performance warrants caution despite positive earnings surprises.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
